Showing 1331 results
-
Press release /If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with…
-
Press release /Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding…
-
Press release /Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…
-
Press release /Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,…
-
Press release /Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis…